Onpoint: How the customized drug Adscepton Works

Foundational to now be available upon physicians patient experiences Sequoia is an adenosine kinase 4 receptor (Akt) antagonist approved by the FDA for treatment of peripheral neuropathy. In peripheral neuropathy patients cannot control their pain-producing neurons. The physician developed a coffee-like adenosine kinase 4 receptor agonist that unblocks pain pathways and functionally reverses the neuropathic pain epidemic.

Prior research findings demonstrate the effectiveness of adenosine kinase 4 (Akt) antagonists in treatment of itch fever migraine and several neuropsychiatric disorders.

At the onset of pain anoikis experience a decrease in spinal excitability and can lead to a critical chronic dyskinesia. Patients taking this neuroactive medication experience severe dyskinesia with an amazing potency and safety profile with limited adverse effects including vomiting and weight loss. At present atypical Akt agonist dronabinol (Xelum) sold as Dakagden by AbbVie has been FDA approved for treatment of moderate to severe allergic disease. Together with other recently developed adenosine kinase 4 (Akt-4) antagonists such as Aczemoz TZ-211 and Tagrissove the companies are actively developing therapies that elicit a strong novel intracranial response in healthy subjects to treat Akt-4-associated neuropathic pain in selected patients.

TZ-211 is a biocompatible adenosine kinase 4 receptor antagonist prescribed to prevent the development of epilepsy. It is currently licensed for the treatment of epilepsy.

Aczemoz is a monoclonal antibody that rapidly induces an anesthetic analgesia in mice with a prominent anti-inflammatory effect on the central nervous system. The drug is licensed for treatment of florbetalmia (severely excessive swelling of the face and body) in a Phase 12a study.

TZ-211 is marketed under the trademarked name Eli Lilly Co Eli Lilly Anesthetic Plus Edition. It has been approved medically by the U. S. and the European Union for oral marketing stockpiling and storage andor delivery to primary healthcare providers and pharmacies in the current Market. As a pharmaceutical candidate it was manufactured at Eli Lillys Rochester Minnesota facility and its pharmacy network.

Aczemoz was licensed to the European Unions marketing on condition for its marketing in the 28 member states. Eli Lilly sold Eli Lilly and Co. the intellectual property rights to the drug. Eli Lilly and its outside intellectual property management is currently under US26 million in liens and approximately US49 million in secured liens to secure the drugs potential sale to the European Union.

A venture capital round led by Sequoia led by Thomas Dunnigan head of the sequencing business division was recently completed and the company expects to have an interim or a full year funding cycle beginning next April. Current funding is set at US5 million up to US10 million more toward the release of new drug candidates.

Sequoia headquartered in Torrance California manufactures at Denvers Anacompa Research Institute a biothermal thermal imaging company and a partner in the multinational LLRR Inc. AstraZeneca partnership to develop an injectable thermal imaging agent for re-engineered enzyme-targeted therapies.

Additional funding comes from the federal Office of the Assistant Secretary for Health the National Institutes of Health and hits for Oncology business intelligence (BIM) Innovation Fund at NIHs National Institute of Allergy and Infectious Diseases (NIH) and the National Comprehensive Cancer Center (NIAID).